Wielage, Ronald; Bansal, Megha; Andrews, J.; Klein, Robert - In: Applied Health Economics and Health Policy 11 (2013) 3, pp. 219-236
The model estimated that duloxetine was potentially cost effective in the base-case population and more cost effective for subgroups over 65 years or at high risk of NSAID-related AEs. In sensitivity analysis, duloxetine dominated all strong opioids in nearly all scenarios. </AbstractSection> Copyright Springer...